Cerus Corporation
CERS US
CERS USCerus Corporation
United States Composite1.67
- Business
- Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Company News
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
Cerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64%
Cerus Corporation: Strong Buy Rating Amidst Growth and Path to Profitability
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Cerus’s Strong Q4 Performance and Positive 2024 Outlook Prompt ‘Buy’ Rating
Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)
Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS)
Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
Earnings Release: Here's Why Analysts Cut Their Cerus Corporation (NASDAQ:CERS) Price Target To US$4.13
Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven
Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript
Cerus Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Cerus Corporation’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
Stifel Nicolaus Keeps Their Buy Rating on Cerus (CERS)
Q4 2023 Cerus Corp Earnings Call
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results